In two weeks, I’ll be participating in the 22nd edition of Endofeminina, in the Symposium: New Evidence in Polycystic Ovary Syndrome (PCOS). My talk, “Epigenetics and cardiometabolic risk,” will focus on how epigenetic changes may help explain cardiometabolic risk in PCOS